[Clinical studies of bestatin on genitourinary cancer].
Bestatin was administered to 20 patients with urogenital tumors. The therapeutic results showed 12 surviving patients and 8 dead patients (including 7 due to cancer and 1 due to a cerebrovascular disorder). One patient has survived for 5 years since bestatin treatment of pulmonary metastasis of renal cancer, and one other patient achieved 5-year survival in spite of systemic metastases of testicular tumor. It is noteworthy that in earlier times these patients could have been expected to experience sudden relapse and aggravation, instead of the long-term survival recorded in this bestatin trial. Studies were conducted on the immunological parameters of the patients before and after the use of bestatin, and it was found that these parameters showed improvement as a result of the treatment. Even though bestatin was ingested for long periods of time by these patients, there was almost no development of adverse reactions to the treatment.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010412:Penile Neoplasms / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D014516:Ureteral Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014565:Urogenital Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D007930:Leucine; C012211:ubenimex